# US 2018/0022734 A1 · Sunitinib prodrug and pharmaceutical composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022734 A1
- Document ID: US20180022734A1
- Status: Published application
- Kind: A1
- Application number: 15/546,599
- Filed: 2016-01-25
- Published: 2018-01-25
- Earliest claimed: 2015-01-28
- Assignees: Sound Biopharmaceuticals Co. Ltd.
- Applicants: Sound Biopharmaceuticals Ltd.
- Inventors: Zhong Wang; Qing Li
- Web page: https://patentgrep.com/patent/US20180022734A1

## CPC

- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K 31/404: Indoles, e.g. pindolol
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a Sunitinib prodrug having formula I, wherein R12, R13 are selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, 4-15 membered heterocyclyl and 5-15 membered heteroaryl; R14 is selected from the group consisting of R′, OR′, SR′ and N(R′)2; and R′ is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, 4-15 membered heterocyclyl, 5-15 membered heteroaryl, hydroxyl C1-C6 alkyl, carboxyl C1-C6 alkyl, C1-C6 alkyl amido and phosphate group. The Sunitinib prodrug of the invention provides better pharmacokinetics and pharmacodynamics, better safety and lower toxicity.

## Claims

### Claim 1

A compound having formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R12, R13 are selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, 4-15 membered heterocyclyl and 5-15 membered heteroaryl;
R14 is selected from the group consisting of R′, OR′, SR′ and N(R′)2; and
R′ is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, 4-15 membered heterocyclyl, 5-15 membered heteroaryl, hydroxyl C1-C6 alkyl, carboxyl C1-C6 alkyl, C1-C6 alkyl amido and phosphate group.

### Claim 2 (depends on 1)

The compound or a pharmaceutically acceptable salt thereof of claim 1, wherein R12, R13 are both H, and R14 is selected from the group consisting of N,N-dimethylaminomethyl, t-butyl, phenyl, p-fluorophenyl, biphenyl, dimethylamino, cyclopropyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, cyclobutyl, pentyl, isopentyl, neopentyl, cyclopentyl, 1-methylcyclobutyl, N-methylamino, N-ethylamino, N,N-methylethylamino, n-hexyl, cyclohexyl, methylthio, ethylthio, propylthio, isopropylthio, cyclopropylthio, butylthio, isobutylthio, cyclobutylthio, methoxy, ethoxy, propoxy, isopropoxy, butoxy, cyclobutoxy, pentylamino, pentylthio, pentyloxy, isopentylamino, neopentylamino, t-butylamino, cyclopentylamino, cyclopentylthio, cyclopentyloxy, cyclohexylamino, cyclohexylthio, cyclohexyloxy, p-methoxyphenyl, p-chlorophenyl and o-fluorophenyl.

### Claim 3 (depends on 1)

The compound or a pharmaceutically acceptable salt thereof of claim 1, wherein R12, R13 are both H, and R14 is t-butyl, phenyl or t-butoxy.

### Claim 4

A compound selected from the group consisting of:
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1-(N,N-dimethylamino)methylcarboxymethyl-2,3-indolin-3-ylmethylene)]-2,4-dimethyl-1H-pyrrolidine-3-carboxamide (Compound A);
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1-(t-butylcarboxymethyl)-2,3-indolin-3-ylmethylene)]-2,4-dimethyl-1H-pyrrolidine-3-carboxamide (Compound 1);
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1-(phenylcarboxymethyl)-2,3-indolin-3-ylmethylene)]-2,4-dimethyl-1H-pyrrolidine-3-carboxamide (Compound 2);
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1-(1-methylcyclobutylcarboxymethyl)-2,3-indolin-3-ylmethylene)]-2,4-dimethyl-1H-pyrrolidine-3-carboxamide (Compound 3);
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1-(N-methylaminocarboxymethyl)-2,3-indolin-3-ylmethylene)]-2,4-dimethyl-1H-pyrrolidine-3-carboxamide (Compound 4);
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1-(N-ethylaminocarboxymethyl)-2,3-indolin-3-ylmethylene)]-2,4-dimethyl-1H-pyrrolidine-3-carboxamide (Compound 5);
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1-(N,N-dimethylaminocarboxymethyl)-2,3-indolin-3-ylmethylene)]-2,4-dimethyl-1H-pyrrolidine-3-carboxamide (Compound 6);
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1-((t-butoxycarboxymethyl)-2,3-indolin-3-ylmethylene)]-2,4-dimethyl-1H-pyrrolidine-3-carboxamide (Compound 7);
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1-(ethoxycarboxymethyl)-2,3-indolin-3-ylmethylene)]-2,4-dimethyl-1H-pyrrolidine-3-carboxamide (Compound 8);
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1-(cyclohexylcarboxymethyl)-2,3-indolin-3-ylmethylene)]-2,4-dimethyl-1H-pyrrolidine-3-carboxamide (Compound 9);
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1-(methylcarboxymethyl)-2,3-indolin-3-ylmethylene)]-2,4-dimethyl-1H-pyrrolidine-3-carboxamide (Compound 10);
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1-(cyclopropylcarboxymethyl)-2,3-indolin-3-ylmethylene)]-2,4-dimethyl-1H-pyrrolidine-3-carboxamide (Compound 11);
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1-(isopropylcarboxymethyl)-2,3-indolin-3-ylmethylene)]-2,4-dimethyl-1H-pyrrolidine-3-carboxamide (Compound 12); and
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1-(p-methoxyphenylcarboxymethyl)-2,3-indolin-3-ylmethylene)]-2,4-dimethyl-1H-pyrrolidine-3-carboxamide (Compound 13),
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

A pharmaceutical composition, comprising an effective amount of a compound or a pharmaceutically acceptable salt thereof of claim 1, and a pharmaceutically acceptable carrier.

### Claim 6 (depends on 1)

A method for treating a cancer, comprising administering to a patient in need thereof an effective amount of a compound or a pharmaceutically acceptable salt thereof of claim 1.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cancer is metastatic renal cell carcinoma, gastrointestinal stromal tumor or liver cancer.
